Across TCGA pan-cancer cohorts, METTL11B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated METTL11B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher METTL11B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL11B expression acts as an unfavorable survival marker.

LIHC and UCEC are the cancer types where METTL11B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: METTL11B tumor-vs-normal RNA expression · all METTL11B data types